Show simple item record

dc.contributor.authorBanerjee, S
dc.contributor.authorTovey, H
dc.contributor.authorBowen, R
dc.contributor.authorFolkerd, E
dc.contributor.authorKilburn, L
dc.contributor.authorMcLachlan, J
dc.contributor.authorHall, M
dc.contributor.authorTunariu, N
dc.contributor.authorAttygalle, A
dc.contributor.authorLima, JPDSN
dc.contributor.authorPerry, S
dc.contributor.authorChatfield, P
dc.contributor.authorHills, M
dc.contributor.authorKaye, S
dc.contributor.authorAttard, G
dc.contributor.authorDowsett, M
dc.contributor.authorBliss, JM
dc.date.accessioned2021-01-28T15:34:31Z
dc.date.available2021-01-28T15:34:31Z
dc.date.issued2020-12-01
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000605562800001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9
dc.identifierARTN 1758835920975352
dc.identifier.citationTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12 pp. ? - ? (13)
dc.identifier.issn1758-8340
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4326
dc.identifier.eissn1758-8359
dc.identifier.doi10.1177/1758835920975352
dc.description.abstractBACKGROUND: Recurrent epithelial ovarian cancer (EOC) remains difficult to treat, with an urgent need for more therapy options. Androgens bind to the androgen receptor (AR), commonly expressed in EOC. CYP17 inhibitor abiraterone irreversibly inhibits androgen biosynthesis. The Cancer of the Ovary Abiraterone (CORAL) trial was designed to evaluate the clinical activity of abiraterone in EOC. PATIENTS & METHODS: CORAL was a multi-centre, open-label, non-randomised, 2-stage phase II clinical trial. Eligible patients had progression within 12 months of last systemic therapy and no prior hormonal anti-cancer agents. Patients received abiraterone 1000 mg daily plus 5 mg prednisone until progression. The primary endpoint was objective response rate (ORR) according to combined Response Evaluation Criteria in Solid Tumours/Gynaecological Cancer Intergroup (RECIST/GCIG) criteria at 12 weeks. Secondary endpoints included clinical benefit rate (CBR) at 12 weeks. RESULTS: A total of 42 patients were recruited; median age 65 (range 34-85) years; 37 (88.1%) had high-grade serous tumours; 20 (48%) had at least three prior lines of therapy; 29/40 (72.5%) were AR+. In stage 1, 1/26 response was observed (in an AR+, low-grade serous EOC); response lasted 47 weeks. Overall, 12 week ORR was 1/42 (2%), CBR was 11/42 (26%) (8/29 (28%) in AR+ patients). Disease control was ⩾6 months for 4/29 (14%). One patient (AR+, low-grade serous) had a RECIST response at 82 weeks. Four (10%) had grade ⩾3 hypokalaemia; 11 (26%) had dose delays. CONCLUSIONS: CORAL represents the first trial of an AR targeted agent in ovarian cancer. While responses were rare, a subset of patients achieved sustained clinical benefit. Targeting AR in EOC including low-grade serous cancer warrants further investigation. TRIAL REGISTRATION: CORAL is registered on the ISRCTN registry: ISRCTN63407050; http://www.isrctn.com/ISRCTN63407050.
dc.format.extent? - ? (13)
dc.languageeng
dc.language.isoeng
dc.publisherSAGE PUBLICATIONS LTD
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectOncology
dc.subjectabiraterone
dc.subjectandrogen receptor
dc.subjectCYP17 inhibitor
dc.subjectlow grade serous
dc.subjectovarian cancer
dc.titleAbiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037).
dc.typeJournal Article
rioxxterms.versionofrecord10.1177/1758835920975352
rioxxterms.licenseref.startdate2020-12-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.publication-statusPublished
pubs.volume12
pubs.embargo.termsNot known
icr.researchteamClinical Trials & Statistics Unit
icr.researchteamMedicine Drug Development Unit (Kaye)
icr.researchteamEndocrinology
icr.researchteamClinical Trials & Statistics Unit
icr.researchteamMedicine Drug Development Unit (Kaye)
icr.researchteamEndocrinology
dc.contributor.icrauthorTovey, Holly
dc.contributor.icrauthorFolkerd, Elizabeth
dc.contributor.icrauthorKilburn, Lucy
dc.contributor.icrauthorBliss, Judith


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record